已收盘 10-02 16:00:00 美东时间
-2.510
-0.96%
Stock index futures were higher on Wednesday as the recent rally in Treasury yields looked to take a breather, while traders turned their focus to several key economic reports. Wall Street’s major mar...
09-30 16:10
今日重点评级关注:HC Wainwright & Co.:维持NeuroSense Therapeutics"买入"评级,目标价从8美元升至52美元;HC Wainwright & Co.:维持艾切托"买入"评级,目标价从27美元升至34美元
09-29 08:33
Truist Securities analyst Jailendra Singh reiterates IQVIA Holdings (NYSE:IQV) with a Buy and raises the price target from $300 to $329.
09-28 23:13
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million in...
09-22 20:16
Amneal Pharmaceuticals announced FDA approval of its lanreotide injection, a long-acting treatment for acromegaly, neuroendocrine tumors, and carcinoid syndrome. The product, referencing SOMATULINE® Depot, received Competitive Generic Therapy (CGT) designation and will launch immediately. With in-house manufacturing, Amneal aims to broaden access and deliver long-term value. U.S. annual sales for SOMATULINE® Depot were $983 million in 2026, per I...
09-18 20:01
今日重点评级关注:Canaccord Genuity:维持Generac Holdings"买入"评级,目标价从275美元升至375美元;巴克莱:维持Oscar Health"超配"评级,目标价从39美元升至49美元
09-18 16:18
Morgan Stanley analyst Kallum Titchmarsh maintains IQVIA Holdings (NYSE:IQV) with a Equal-Weight and raises the price target from $240 to $270.
09-17 23:52
LB Pharmaceuticals Inc announced the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer. Dr. Kozauer brings over two decades of experience in neuropsychiatric drug development, including schizophrenia, mood disorders, and neurodegenerative diseases. She previously led clinical development at Intra-Cellular Therapies and Centessa Pharmaceuticals. LB Pharmaceuticals is advancing its Phase 3 NOVA-2 trial for LB-102, a potential first be...
09-15 12:00
SCYNEXIS appoints Todd Minga, M.D., as Senior Vice President, Research & Development. Dr. Minga brings over 20 years of experience in kidney disease and rare disorders, previously serving as Vice President, Medical Affairs and Clinical Development at Akebia Therapeutics. His expertise will support SCYNEXIS in advancing its rare disease programs, including SCY-770 for ADPKD and SCY-247. Dr. Minga expressed excitement about contributing to the Comp...
09-15 12:00
诺华制药大升5.19%;Pershing Square上升4.85%;Robinhood上升4.02%
09-01 15:01